Sort   by:  
 Page size 
TranscriptomicsExpression data from prostate cancer cell lines C4-2B (enzalutamide sensitive) and C4-2B-MDVR (enzalutamide resistant) cells
Prostate cancer C4-2B cells were cultured in enzalutamide in a dose-escalation manner. After sixty passages cells were resistant to enzalutamide, with a specific sets of genes been deregulated. We performed global gene expression analysis by cDNA microarrays to identify genes responsible for enzalut...
ORGANISM(S): Homo sapiens 
2015-04-09 | E-GEOD-64143 | biostudies-arrayexpress
TranscriptomicsExpression data from LNCaP cells treated with DHT and enzalutamide
Enzalutamide (formerly MDV3100 and available commercially as Xtandi), a novel androgen receptor (AR) signaling inhibitor, blocks the growth of castration-resistant prostate cancer (CRPC) in cellular model systems and was shown in a clinical study to increase survival in patients with metastatic CRPC...
ORGANISM(S): Homo sapiens 
2013-04-01 | E-GEOD-44905 | biostudies-arrayexpress
TranscriptomicsAcquired Resistance to the Second-Generation Androgen Receptor Antagonist Enzalutamide in Castration-Resistant Prostate Cancer
Illumina gene array analyses of prostate cancer cell lines that had acquired resistance to Enzalutamide (MDV3100). mRNA analyses of four cell lines (CWR-R1, LAPC-4, LNCaP, and VCAP) cells that were either untreated, treated for 48hrs with Enz (short-term), or continuously grown in Enzalutamide for >...
ORGANISM(S): Homo sapiens 
2016-02-24 | E-GEOD-78201 | biostudies-arrayexpress
TranscriptomicsRNA-Seq analysis of prostate tumors with or without androgen receptor splice variant
Background. Androgen receptor splice variant-7 (AR-V7) is a truncated form of the androgen receptor protein which lacks the ligand-binding domain, the target of enzalutamide and abiraterone, but remains constitutively active as a transcription factor. We hypothesized that detection of AR-V7 in circ...
ORGANISM(S): Homo sapiens 
2014-09-03 | E-GEOD-56701 | biostudies-arrayexpress
ProteomicsFMNL2/SRC-mediated androgen receptor translocation into the nucleus promotes enzalutamide resistance of prostate cancer
Enzalutamide, a second-generation androgen receptor (AR) antagonist, has represented the association with improved overall survival in men with prostate cancer (PCa). However, PCa patients receiving enzalutamide will eventually develop resistance through various mechanisms without effective regimens...
ORGANISM(S): Homo sapiens (Human) 
2025-01-13 | PXD059539 | Pride
Ar Fmnl2 Prostate cancer，enzalutamide resistance 
TranscriptomicsCellular androgen content influences enzalutamide agonism of F877L mutant androgen receptor
Prostate cancer is the most commonly diagnosed and second-most lethal cancer among men in the United States. The vast majority of prostate cancer deaths are due to castration-resistant prostate cancer (CRPC) â?? the lethal form of the disease that has progressed despite therapies that interfere with...
ORGANISM(S): Homo sapiens 
2016-06-10 | E-GEOD-69896 | biostudies-arrayexpress
GenomicsEnzalutamide resistance in prostate cancer cells
Enzalutamide resistance in prostate cancer cells
PRJNA633640 | ENA
GenomicsChromatin binding alteration after enzalutamide treatment
Chromatin binding alteration after enzalutamide treatment
PRJNA824030 | ENA
TranscriptomicsLNCAP/AR and a LnCAP/AR subline (LREX') with acquired resistance to 2nd generation antiandrogens
The treatment of advanced prostate cancer has been transformed by novel antiandrogen therapies such as enzalutamide. Using the LnCaP/AR xenograft model, we identified induction of glucocorticoid receptor (GR) expression as a common feature of drug resistant tumors. From a resistant xenograft tumor...
ORGANISM(S): Homo sapiens 
2013-12-27 | E-GEOD-51873 | biostudies-arrayexpress
GenomicsIdentification of Genes Promoting Resistance to Enzalutamide
Identification of Genes Promoting Resistance to Enzalutamide
PRJNA659253 | ENA
Sort   by:  
 Page size